NLS Pharmaceutics (NLSP) Stock Price, News & Analysis

Company Overview

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Key Stats

• Today's Range: $1.99 to $2.18
• 50-Day Range: $1.80 to $2.90
• 52-Week Range: $1.30 to $8.20
• Volume: 156,943 shs
• Average Volume: 1.11 million shs
• Market Capitalization: $7.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NLSP Stock Analysis - Frequently Asked Questions

How have NLSP shares performed this year?

NLS Pharmaceutics' stock was trading at $2.11 at the beginning of 2025. Since then, NLSP shares have increased by 1.4% and is now trading at $2.14.

When did NLS Pharmaceutics IPO?

NLS Pharmaceutics (NLSP) raised $20 million in an IPO on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NLS Pharmaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Tesla (TSLA).

Company Calendar

• Today: 8/08/2025
• Next Earnings (Estimated): 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NLSP
• CIK: 1783036
• Web: www.nlspharma.com
• Phone: 41-44-512-2150
• Fax: 41-41-618-8009
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.69
• Quick Ratio: 2.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.37) per share
• Price / Book: -5.57

Miscellaneous

• Outstanding Shares: 3,600,000
• Free Float: 3,008,000
• Market Cap: $7.42 million
• Optionable: Not Optionable
• Beta: 0.15